---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-096438"
form_type: "8-K"
ticker: "CLSDQ"
cik: "0001539029"
company_name: "Clearside Biomedical, Inc."
filed_at: "2025-07-17T23:59:59+00:00"
generated_at: "2026-05-18T05:57:30.490531+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Clearside explores strategic alternatives; all employees terminated, R&D paused

## Summary
- All employees, including CEO, CFO, CMO, terminated effective July 18, 2025, transition to consulting roles.
- Estimated $3.4M severance charges in Q3 2025; internal R&D programs paused.
- Retained Piper Sandler to evaluate sale, license, merger, or other strategic transactions.
- No agreement reached; no timetable set; no assurance any transaction will occur.
- CLS-AX Phase 3-ready in wet AMD; SCS Microinjector platform with five licensing partners.

## SEC filing metadata
- accession: 0000950170-25-096438
- form_type: 8-K
- ticker: CLSDQ
- cik: 0001539029
- company_name: Clearside Biomedical, Inc.
- filed_at: 2025-07-17T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.05, 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1539029/000095017025096438/0000950170-25-096438-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1539029/000095017025096438/clsd-20250717.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-096438
- JSON: https://secwatch.observer/filing/0000950170-25-096438.json
- Plain text: https://secwatch.observer/filing/0000950170-25-096438.txt

## Key facts
- Restructurings & Charges
  Clearside Biomedical, Inc. announced a restructuring with charges of approximately $3.4 million for severance and other employee termination-related costs affecting the Company (all Clearside employees).
  - Type: restructuring
  - Charge: approximately $3.4 million for severance and other employee termination-related costs
  - Affected area: the Company
  - Headcount: all Clearside employees
  source text: On July 17, 2025, Clearside Biomedical, Inc. (the “ Company ”) announced that it is exploring strategic alternatives to enhance shareholder value, and that in connection with such process and in order to extend the Company’s resources, the Company is implementing a plan pursuant to which all Clearside employees will have their employment with the Company terminated and will transition into consulting roles with the Company. The reduction in force is expected to be completed during the third quarter of 2025. The Company estimates that it will incur charges of approximately $3.4 million for severance and other employee termination-related costs in the third quarter of 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1539029/000095017025096438/0000950170-25-096438-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.